CEACAM1 and familial pancreatic carcinoma: A clinical study found that CEACAM1 was expressed in the sera of 24% (15/61) of normal patients, 66% (35/53) of patients with chronic pancreatitis, and 91% (74/81) of pancreatic cancer patients, indicating that CEACAM1 may be a viable biomarker for pancreatic cancer [97, 98].